Ailene Medalla
Family Medicine · Chesapeake, VANPI 1508252461
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. 2023 is the largest year on record at $1,004, 2.1 times the $480 reported in 2019.
Across 166 payments — averaging $15.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$551
- Novo Nordisk$437
- Pfizer$212
- Amarin Pharma, Inc.$114
- GSK$112
- Merck$111
- plus $998 from 27 others
What the payments were for
- Food & beverage$2,534100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 39 | $551 |
| Novo Nordisk | 29 | $437 |
| Pfizer | 16 | $212 |
| Amarin Pharma, Inc. | 7 | $114 |
| GSK | 6 | $112 |
| Merck | 8 | $111 |
| Lilly USA, LLC | 8 | $110 |
| Abbott | 6 | $106 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $100 |
| Boehringer Ingelheim | 5 | $81 |
| Tris Pharma Inc | 4 | $71 |
| Sanofi Pasteur Inc. | 2 | $48 |
| Medtronic | 1 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $38 |
| Genentech USA, Inc. | 3 | $38 |
| Amgen | 2 | $33 |
| AstraZeneca | 2 | $31 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Dermira, Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| Shield Therapeutics Inc | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Cranial Technologies, Inc | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Shire North American Group Inc | 1 | $15 |
| Scynexis, Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$2,534 in reported general payments places this provider in the 80th percentile of 2,553 family medicine providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 87 | $730 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 12 | $529 |
| Losartan Potassium | 49 | $477 |
| Ezetimibe | 15 | $456 |
| Levothyroxine Sodium | 32 | $398 |
| Amlodipine Besylate | 47 | $314 |
| Metoprolol Succinate | 19 | $308 |
| Lisinopril | 32 | $303 |
| Famotidine | 24 | $299 |
| Pravastatin Sodium | 22 | $291 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 26 | $286 |
| Montelukast Sodium | 30 | $266 |
| Metformin Hcl ErMetformin Hcl | 21 | $224 |
| Hydrochlorothiazide | 20 | $190 |
| Potassium Chloride | 13 | $178 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Chesapeake
- Ronald AtwoodChesapeake$15K
- Eleanor Deguzman-BerubeChesapeake$14K
- Oluwaronke AwosikaFort Gregg Adams$397K
- Monique MatuskowitzNorfolk$110K
- Paul StairsRichmond$105K
- Edwin RobinsonRichmond$83K
- Benjamin PhilpottRocky Mount$64K
- John MolaiyArlington$64K
- Catherine VarneyZion Crossroads$47K
- Jordan TranWinchester$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.